珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance
2026年10月27日 04:14:33来源:作者:
【摘要】 Ad hoc announcement pursuant to Art. 53 LRZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026.

Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026.

  • Record net sales of 4.765 billion USD for the first nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix.
  • Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators.
  • Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD).
  • Strengthening Galderma’s dermatology platform, with the previously announced agreement to acquire ZO® Skin Health, a leading brand in the fast-growing physician-dispensed skincare category. The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary closing conditions.
  • Further evolution as a listed company, with Galderma’s inclusion in the Swiss Market Index (SMI) and an upgraded credit rating.
  • Raising 2026 full-year net sales guidance to 22.5-23.5% growth year-on-year at constant currency (previously 19-21%), and confirming Core EBITDA margin2 of approximately 26% at constant currency.

 

“Our strong performance in the first nine months of 2026 underscores the sustained momentum across our business and the strength of our integrated dermatology strategy. Robust demand for our differentiated, premium portfolio continues to drive growth, while we advance innovation and take decisive steps to strengthen our long-term growth prospects, including our agreement to acquire ZO Skin Health. Building on this momentum and our confidence in the business, we are raising our full-year net sales guidance.”

 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

GALDERMA

 

 

责任编辑: admin

看新闻,关注新闻

本网网友:苏素/mmmmm
评论:法国有个圣女,叫贞德。中国有好多剩女,是真的。

腾讯网友:渲染那份寂寞
评论:我的优点:勇于认错;缺点:坚决不改。

淘宝网友:Leians-旧人心
评论:对于男人而言,前女友就好象是亲生的,后女友就像是领养的。

百度网友:哥只是寂寞
评论:别叫我忘了你,我根本就没记住你

天涯网友:我依舊依賴你
评论:这么不要脸,这么没心没肺,你的体重应该会很轻吧

凤凰网友:迷情queen°
评论:我也曾有过一双翅膀,不过我没用它在天上翱翔,而是放在锅里炖汤

猫扑网友:笨笨Forever〃
评论:好的爱情,战得胜时间,抵得住流年,经得起离别,受得住想念。

网易网友:私念° 7/m
评论:真怀念小时候啊,天热的时候我也可以像男人一样光膀子。

搜狐网友:蓅姩媣栺圊舂
评论:有一天,全世界都不要你了。不要慌,来找我,我会告诉你,我也不要你。

其它网友:強悍的是命運
评论:好名声是女人最体面的嫁妆。

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!